Single-center experience in the diagnosis and treatment of hepatic angiosarcoma.

IF 2.1 4区 医学 Q3 ONCOLOGY
Jian Yu, Junjun Jia, Jiabin Liu, Zhou Shao, Feng Gao, Songfeng Yu, Min Zhang
{"title":"Single-center experience in the diagnosis and treatment of hepatic angiosarcoma.","authors":"Jian Yu, Junjun Jia, Jiabin Liu, Zhou Shao, Feng Gao, Songfeng Yu, Min Zhang","doi":"10.21037/cco-24-116","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Primary hepatic angiosarcoma (PHA) is a rare but aggressive liver tumor, accounting for ~5% of all hemangiosarcomas and <2% of all primary hepatic malignancies. Oncological treatment data on PHA remain limited at present. The objective of this single-center study was to summarize the diagnosis and treatment of PHA, thereby contributing additional clinical data to improve understanding of the disease.</p><p><strong>Methods: </strong>Eight patients were diagnosed with PHA in The First Affiliated Hospital, Zhejiang University School of Medicine from 2016 to 2022. Five patients were male and three were female with a mean age of 62.4 years (range, 38-74 years). We summarized the clinical characteristics, pathological parameters, and treatment based on the electronic medical record system.</p><p><strong>Results: </strong>Among the 8 patients with PHA, four patients presented with abdominal distension and pain, and two with weakness. The diagnosis was confirmed by pathological findings. Four patients underwent surgery and four received conventional treatment. Seven patients died within 14 months due to tumor progression and the median survival time was 2 months.</p><p><strong>Conclusions: </strong>PHA is a rare malignant liver tumor, and there are no specific symptoms or imaging methods for preoperative diagnosis. The diagnosis can only be confirmed by pathology and the prognosis is poor. Early diagnosis is crucial and further studies are needed to develop standardized diagnostic and treatment guidelines.</p>","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":"14 3","pages":"28"},"PeriodicalIF":2.1000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chinese clinical oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/cco-24-116","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Primary hepatic angiosarcoma (PHA) is a rare but aggressive liver tumor, accounting for ~5% of all hemangiosarcomas and <2% of all primary hepatic malignancies. Oncological treatment data on PHA remain limited at present. The objective of this single-center study was to summarize the diagnosis and treatment of PHA, thereby contributing additional clinical data to improve understanding of the disease.

Methods: Eight patients were diagnosed with PHA in The First Affiliated Hospital, Zhejiang University School of Medicine from 2016 to 2022. Five patients were male and three were female with a mean age of 62.4 years (range, 38-74 years). We summarized the clinical characteristics, pathological parameters, and treatment based on the electronic medical record system.

Results: Among the 8 patients with PHA, four patients presented with abdominal distension and pain, and two with weakness. The diagnosis was confirmed by pathological findings. Four patients underwent surgery and four received conventional treatment. Seven patients died within 14 months due to tumor progression and the median survival time was 2 months.

Conclusions: PHA is a rare malignant liver tumor, and there are no specific symptoms or imaging methods for preoperative diagnosis. The diagnosis can only be confirmed by pathology and the prognosis is poor. Early diagnosis is crucial and further studies are needed to develop standardized diagnostic and treatment guidelines.

肝血管肉瘤的单中心诊治经验。
背景:原发性肝血管肉瘤(Primary liver angiosarcoma, PHA)是一种罕见但侵袭性的肝脏肿瘤,占所有血管肉瘤的约5%。方法:2016 - 2022年,浙江大学医学院第一附属医院共确诊8例肝血管肉瘤。男性5例,女性3例,平均年龄62.4岁(38-74岁)。我们总结了基于电子病历系统的临床特点、病理参数和治疗方法。结果:8例PHA患者中,4例出现腹胀疼痛,2例出现虚弱。病理结果证实了诊断。4例患者接受手术治疗,4例接受常规治疗。7例患者因肿瘤进展在14个月内死亡,中位生存时间为2个月。结论:PHA是一种罕见的肝脏恶性肿瘤,术前无特定的症状和影像学诊断方法。诊断只能通过病理证实,预后较差。早期诊断至关重要,需要进一步研究以制定标准化的诊断和治疗指南。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.90
自引率
0.00%
发文量
0
期刊介绍: The Chinese Clinical Oncology (Print ISSN 2304-3865; Online ISSN 2304-3873; Chin Clin Oncol; CCO) publishes articles that describe new findings in the field of oncology, and provides current and practical information on diagnosis, prevention and clinical investigations of cancer. Specific areas of interest include, but are not limited to: multimodality therapy, biomarkers, imaging, tumor biology, pathology, chemoprevention, and technical advances related to cancer. The aim of the Journal is to provide a forum for the dissemination of original research articles as well as review articles in all areas related to cancer. It is an international, peer-reviewed journal with a focus on cutting-edge findings in this rapidly changing field. To that end, Chin Clin Oncol is dedicated to translating the latest research developments into best multimodality practice. The journal features a distinguished editorial board, which brings together a team of highly experienced specialists in cancer treatment and research. The diverse experience of the board members allows our editorial panel to lend their expertise to a broad spectrum of cancer subjects.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信